Baseline hs-CRP predicts hypertension remission in metabolic syndrome
| Autor: | Silvia Minetti, Nathan Artom, Daniela Verzola, Roberto Pontremoli, Aldo Bonaventura, Giorgio Luciano Viviani, Franco Dallegri, Luca Liberale, Federico Carbone, Matteo Casula, Livia Pisciotta, Maria Bertolotto, Franesca Viazzi, Fabrizio Montecucco, Paola Contini, Stefano Bertolini, Aldo Pende, Edorado Elia |
|---|---|
| Přispěvatelé: | University of Zurich, Carbone, Federico |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty obesity 1303 Biochemistry Waist hypertension Remission Spontaneous Clinical Biochemistry 610 Medicine & health 1308 Clinical Biochemistry 030204 cardiovascular system & hematology Overweight Systemic inflammation Biochemistry metabolic syndrome C-reactive protein 11459 Center for Molecular Cardiology Cohort Studies Young Adult 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans overweight 030212 general & internal medicine Antihypertensive Agents Anthropometry biology business.industry General Medicine Middle Aged medicine.disease Obesity Diet C-reactive protein hypertension inflammation metabolic syndrome obesity overweight Blood pressure ROC Curve inflammation Cohort Metabolome biology.protein Female Waist Circumference medicine.symptom Metabolic syndrome business |
| Popis: | BACKGROUND Inflammation, overweight and other cardiovascular risk factors might negatively impact on hypertension remission in metabolic syndrome (MetS), independently of the pharmacological treatment. Here, the potential influence of systemic inflammation (assessed by serum high-sensitivity C-reactive protein [hs-CRP]) on hypertension remission will be investigated in a cohort of hypertensive patients with MetS. MATERIAL AND METHODS Hypertensive patients with MetS (n = 100) were enrolled, treated under current behavior/dietary/pharmacological recommendations and followed up for 12 months. All patients received medications and nutritional advice based on Mediterranean-like dietary pattern in addition to psychological and physical activity counselling. At baseline (T0), 6 (T1) and 12 (T2) months of follow-up, clinical data, haematological and biochemical profiles and serum hs-CRP were measured. RESULTS As compared to T0, at T2 patients displayed improvements in anthropometric and metabolic profiles. At T2, the hypertension remission rate was 13.0%. Serum hs-CRP did not change overtime in the overall cohort. Surprisingly, patients who experienced hypertension remission were less treated with antihypertensive drugs, but developed a weak improvement in anthropometric measures during follow-up. The hypertension remission group had lower baseline levels of hs-CRP as compared to non-remission. Low baseline hs-CRP ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|